Perceptive Advisors' healthcare SPAC, ARYA Sciences Acquisition V prices $130 million IPO

ARYA Sciences Acquisition V, the fifth healthcare-focused blank check company formed by Perceptive Advisors, raised $130 million by offering 13 million shares at $10.

The offering does not contain warrants. The company may raise an additional $25 million at the closing of an acquisition pursuant to a forward purchase agreement with the sponsor.

The company is led by Chairman Joseph Edelman, who serves as Founder and CEO of Perceptive Advisors; CEO and Director Adam Stone, who serves as Chief Investment Officer of Perceptive Advisors; and CFO and Director Michael Altman, who is a Managing Director at Perceptive Advisors.

The team's previous SPACs include ARYA Sciences Acquisition IV (ARYD; +5.9% from offering price); ARYA Sciences Acquisition III, which recently completed its acquisition with Nautilus Biotechnology (NAUT; 0.0% return); ARYA Sciences Acquisition II, which completed its acquisition of Cerevel Therapeutics (CERE; +135%) in October 2020; and ARYA Sciences Acquisition, which completed its acquisition of Immatics Biotechnologies (IMTX; +20%) in July 2020.

ARYA Sciences Acquisition V plans to target the healthcare industry, with a specific focus on North American or European companies in the life sciences and medical technology sectors where management has extensive investment experience.

ARYA Sciences Acquisition V plans to list on the Nasdaq under the symbol ARYE. Jefferies and Goldman Sachs acted as joint bookrunners on the deal.